EUVIMEDObjevte EUVIMED
Crossref

IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease

Navneet Natt, Monica Gindi, Gio R Dela Cruz, Terry Ponich, James C Gregor, Nilesh Chande, Melanie D Beaton, Keith McIntosh, Michael Sey, Reena Khanna, Richard B Kim iD, Aze Wilson iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70377 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Navneet Natt and 11 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Medicine, Western University, London, Ontario, Canada. Major MEDLINE topics: Receptors, Interleukin, Inflammatory Bowel Diseases, Psoriasis, Tumor Necrosis Factor-alpha. 33 references. Funded by: CIHR, Wolfe Pharmacogenomics Research Chair, Academic Medical Organization of Southwestern Ontario.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Paradoxical psoriasis (PP) is an adverse drug reaction associated with anti‐tumour necrosis factor (TNF)‐α therapy leading to disfiguring skin lesions that may impact an individual's quality of life and affect their inflammatory bowel disease (IBD) care. To date, there are no tools to identify individuals at risk for PP. IL‐23 receptor (IL23R) gene polymorphisms have been linked to psoriasis and may be implicated in PP.

Aims

To evaluate the association between the IL23R1142G>A single nucleotide variant and the occurrence of PP in an anti‐TNFα‐treated IBD population and assess other clinical variables associated with PP development.

Methods

In a retrospective cohort study conducted in anti‐TNFα‐exposed adult patients with IBD, participants were screened for the IL23R1142G>A variant genotype and the occurrence of PP was assessed. Participants were additionally assessed for clinical variables associated with PP development and for the impact of PP on IBD treatment.

Results

Among 499 patients, the incidence of PP was 5.1% (29/570) with 570 unique anti‐TNFα exposures. Most patients had severe PP (69.0%) and required treatment cessation (69.0%), which resulted in complete resolution of PP. An IL23R1142G>A variant genotype was highly associated with PP development (46.2% vs. 5.1%, OR = 17.8, 95% CI 7.8–40.0; p < 0.0001). No other clinical variables were associated with the occurrence of PP.

Conclusions

Variation in the IL23R gene may identify those at risk of anti‐TNFα‐induced PP, beyond clinical variables. Further validation of this finding may promote its utility as a clinically actionable tool for the safe delivery of IBD medical therapy.

Subjects

MeSH terms (MEDLINE)

Receptors, InterleukinInflammatory Bowel DiseasesPsoriasisTumor Necrosis Factor-alphaPolymorphism, Single NucleotideHumansMaleFemaleAdultRetrospective StudiesMiddle AgedGenotypeCohort StudiesAged

Author keywords

Crohn's diseaseinflammatory bowel diseaseparadoxical psoriasistumour necrosis factor‐α inhibitorsulcerative colitis

Substances

Receptors, InterleukinTumor Necrosis Factor-alphaIL23R protein, human

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Medicine, Western University, London, Ontario, Canada.
  • Department of Medicine, Western University, London, Ontario, Canada.
  • Division of Clinical Pharmacology and Toxicology, Department of Medicine, Western University, London, Ontario, Canada.
  • Southwestern Ontario Inflammatory Bowel Disease Clinic, London, Ontario, Canada.
  • Department of Physiology & Pharmacology, Western University, London, Ontario, Canada.

ORCID profiles: Richard B Kim, Aze Wilson

Funding

  • CIHR
  • Wolfe Pharmacogenomics Research Chair
  • Academic Medical Organization of Southwestern Ontario
  • Canadian Institutes of Health Research

Cite

APA

Natt, N., Gindi, M., Dela Cruz, G. R., Ponich, T., Gregor, J. C., Chande, N., Beaton, M. D., McIntosh, K., Sey, M., Khanna, R., Kim, R. B., & Wilson, A. (2026). IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70377

Vancouver

Natt N, Gindi M, Dela Cruz GR, Ponich T, Gregor JC, Chande N, et al. IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70377

BibTeX
@article{Natt2026,
  author = {Natt, Navneet and Gindi, Monica and Dela Cruz, Gio R and Ponich, Terry and Gregor, James C and Chande, Nilesh and Beaton, Melanie D and McIntosh, Keith and Sey, Michael and Khanna, Reena and Kim, Richard B and Wilson, Aze},
  title = {IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70377}
}
Start for free →